Miles Goodman Siegel is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as CGRP receptor antagonists. With a total of 11 patents to his name, Siegel's work has had a substantial impact on medical research and drug development.

Latest Patents

Among his latest patents, Siegel has developed compounds such as 3-methyl-pyrrolidine-2,5-dione derivatives, which are useful as CGRP receptor antagonists. The present invention provides a compound of Formula II or a pharmaceutically acceptable salt or hydrate thereof, which is beneficial in treating various medical conditions. Additionally, he has patented CGRP receptor antagonists, further showcasing his innovative approach to pharmaceutical solutions.

Career Highlights

Miles Goodman Siegel is currently associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development in the field of pharmaceuticals.

Collaborations

Some of his notable coworkers include Russell Dean Stucky and James E Fritz. Their collaborative efforts have led to advancements in drug development and have strengthened the research initiatives at Eli Lilly.

Conclusion

Miles Goodman Siegel's contributions to pharmaceutical chemistry and his innovative patents have positioned him as a key figure in the industry. His work continues to influence the development of new therapeutic options, making a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.